Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Open House Original Rebate Agreements 2023-02 - Lamivudine/Abacavir/Dolutegravir (Drug Combination)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Biologics Rebate Contracts 2022-24 - Natalizumab (Dosage Form for Subcutaneous Injection)

Open House Biologics Rebate Agreements 2022-23 - Natalizumab (Dosage Form for Intravenous Use)

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Mepolizumab (Atc Code: R03dx09).

Degree Non-Excl. am Discount Agreements According to Section 130A (8) Sgb V by Means of a So-Called Open-House Model for the Active Substance Perindopril/Indapamide (Atc Code According to Who: C09ba04; Official Atc Code: C09ba54)

Completion Non-exkl. Am Discount Agreements According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Perindopril/indapamide (atc Code According to Who: C09ba04; Amtl. Atc Code: C09ba54)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Biologics Rebate Contracts 2022-22 - Peginterferon Beta-1A

Open House Discount Contracts 2022-20